🔗 Share this article

As the US proceeds with sweeping adjustments to its immunization guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by casting doubt on COVID-19 vaccinations throughout the pandemic and has focused upon potential fatalities after COVID-19 immunization in her short time at the FDA.

Planned Shifts to Pediatric Immunization Program

Health officials planned to reveal major changes to the pediatric vaccine schedule earlier this month, aligning the US with the Danish immunization schedule, sources say – a significant shift that would put the US at odds with much of the international standard with insufficient data for improved outcomes. This reveal has been pushed back until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is listed to present at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the division this year.

A Shift at the Agency

The acting appointment may indicate a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the agency – and it signals a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has frequently advocated for halting certain childhood shot schedules in the US to become more in line with the Danish model, a nation with comprehensive healthcare and a number of inhabitants about the size of the state of Wisconsin.

To date public appearances, she has continued to focus on immunizations – usually the purview of Prasad, head of the FDA’s vaccine center – instead of drug regulation.

Concerns Over Qualifications

Høeg has no apparent experience in drug development, regulation or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, stated a neurologist and psychiatrist. “She lacks experience running a clinical trial. She is not versed in managing a major agency. She has no expertise in drug approvals.”

Past directors of CBER would “understand regulatory frameworks and the underlying principles of drug development”, noted a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that former directors who ran CBER have had.”

This division has an vast workload at the FDA, she stated.

“Everybody just focuses on the new drug program, but the generic drug division approves thousands of generic medications. There’s a biosimilars program, OTC medication office and so forth, and every single one need to be managed,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a major leadership element to the job, which oversees over 5,000 personnel. “It is a huge administrative position, if you execute it properly,” Woodcock said.

Response and Disputed Programs

Regarding concerns about Høeg’s fitness for the role and whether this assignment indicates increased cooperation among regulatory chiefs on vaccines, a representative said that the “questions stem from incorrect assumptions”.

“Her experience aligns with the responsibilities of her position,” the spokesperson explained, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a disputed rapid therapy clearance system that apparently troubled her former heads. “How are these drugs being chosen for this fast-track system? Who is making the decisions?” Dr. Howard asked. “There’s a lot of secrecy going on at the regulatory body right now.”

Broadly speaking, he stated, “the agency seems to be moving towards laxer rules of pharmaceuticals, except for vaccines.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more documented, if troubling, past, Howard observe. She authored a research paper using non-validated crowd-sourced reports to assess the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to suggest COVID-19 vaccinations are riskier than they are.

Included in her “desired changes” for the incoming government featured revising regulations for recently developed shots and discontinuing “optional” vaccines, she remarked post-election on a audio program. At the FDA, Høeg has reportedly proposed preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an complete true believer who commences with her preconceived notions and reverse-engineers to retrofit the data in a very deceptive, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|